ImmunoGen Gains Momentum On Success Of T-DM1, The Herceptin Conjugate In Development By Roche/Genentech
This article was originally published in The Pink Sheet Daily
Executive Summary
Buoyed by the affirmation of its conjugation technology brought by the imminent filing of T-DM1, ImmunoGen is focused on building an internal pipeline with future emphasis co-development deals, not just outlicensing.
You may also be interested in...
Roche's T-DM1 Early Filing Strategy Backfires As FDA Refuses To File BLA
It hasn't been a swell summer for Roche, and now a bit of near-term pipeline news that could have put the company on a more positive trajectory has fallen flat. FDA refused to file Roche's BLA for breast cancer agent trastuzumab-DM1 (T-DM1), a conjugated version of Herceptin, for accelerated approval, the company announced Aug. 27
Roche's T-DM1 Early Filing Strategy Backfires As FDA Refuses To File BLA
It hasn't been a swell summer for Roche, and now a bit of near-term pipeline news that could have put the company on a more positive trajectory has fallen flat. FDA refused to file Roche's BLA for breast cancer agent trastuzumab-DM1 (T-DM1), a conjugated version of Herceptin, for accelerated approval, the company announced Aug. 27
Roche's T-DM1 Early Filing Strategy Backfires As FDA Refuses To File BLA
FDA refused to file Roche's BLA for breast cancer agent trastuzumab-DM1, a conjugated version of Herceptin, for accelerated approval, the company announced Aug. 27.